NVAF

(redirected from Non-Valvular Atrial Fibrillation)
AcronymDefinition
NVAFNon-Valvular Atrial Fibrillation
NVAFNorth Vietnamese Air Force
NVAFNieuwe Vrije Agrarische Federatie (Dutch: Free New Agrarian Federation)
NVAFNet Volume Adjustment Factor (Ministry of Sustainable Resource Management; Canada)
NVAFNon-Valvular Auricular Fibrillation
References in periodicals archive ?
Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
People aged 65 and older with non-valvular atrial fibrillation are approximately three to five times more likely to have a stroke than those without this disorder,iii,iv,v said Christoph Koenen, M.
The outcomes measured in this study were the occurrence of acute stroke, systemic embolism, major bleeding, clinically relevant non-major bleeding, and all-cause death in non-valvular atrial fibrillation patients undergoing cardioversion.
Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non-valvular atrial fibrillation and moderate renal impairment.
Rivaroxaban versus warfarin in non-valvular atrial fibrillation.
It was reported yesterday that the project concentrates on non-valvular atrial fibrillation and will examine disease prevalence, treatment complications, such as hospital readmissions, and the use of evidence-based guidelines.
Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): Randomised controlled trial.
J-ROCKET AF was a smaller study (1,280 patients randomized) that was performed to evaluate the safety of Xarelto versus warfarin in patients with non-valvular atrial fibrillation living in Japan.
Pradaxa represents an exciting new treatment option for patients with non-valvular atrial fibrillation.
The US Food and Drug Administration (FDA) has approved PradaxaA (dabigatran etexilate),1 Boehringer Ingelheim's novel, oral direct thrombin inhibitor2 for stroke risk reduction in patients with non-valvular atrial fibrillation (AF) marking the first approval of a new oral anticoagulant in the U.
Responses to the statement: "In my opinion, patients with non-valvular atrial fibrillation and the following features should not be anticoagulated with warfarin"
Full browser ?